CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's...
Phase 3
Centerville, Ohio, United States and 70 other locations
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease...
Phase 2, Phase 3
Dayton, Ohio, United States and 89 other locations
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...
Phase 2, Phase 3
Centerville, Ohio, United States and 27 other locations
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elder...
Phase 2
Beavercreek, Ohio, United States and 63 other locations
versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...
Phase 2
Cincinnati, Ohio, United States and 101 other locations
be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...
Phase 2
Centerville, Ohio, United States and 168 other locations
The objective of this study is to determine the safety and tolerability of fosgonimeton (ATH-1017) in subjects with mild to moderate Alzheimer's...
Phase 2, Phase 3
Dayton, Ohio, United States and 50 other locations
A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's...
Phase 2
Cincinnati, Ohio, United States and 91 other locations
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to e...
Phase 3
Dayton, Ohio, United States and 74 other locations
female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis rela...
Phase 3
Dayton, Ohio, United States and 63 other locations
Clinical trials
Research sites
Resources
Legal